Results 81 to 90 of about 12,929 (204)

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, EarlyView.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Table_1_A Novel Prognostic Signature Based on Ferroptosis-Related Genes Predicts the Prognosis of Patients With Advanced Bladder Urothelial Carcinoma.xlsx [PDF]

, 2021
Bladder Urothelial Carcinoma (BLCA) is the major subtype of bladder cancer, and the prognosis prediction of BLCA is difficult. Ferroptosis is a newly discovered iron-dependent cell death pathway.
Chunxue Li (8263752), Yajing Wang (447120), Jianjian Zheng (839446), Ji Chen (69329), Wujun Geng (10332453), Enze Lu (11828303), Yuxiao Zhang (2040100), Yating Zhan (5048351), Yeping Li (5100695), Xiaoqi Li (3592895), Rongrong Zhang (217915), Junting Huang (389484)   +11 more
core   +1 more source

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

European Journal of Haematology, EarlyView.
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley   +1 more source

PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma

Scientific Reports, 2023
Abnormal proline-rich protein 11 (PRR11) expression is associated with various tumors. However, there are few reports concerning PRR11 with prognostic risk, immune infiltration, or immunotherapy of bladder urothelial carcinoma (BLCA). This study is based
Wenpeng Ni, Lijuan Yi, Xiaoru Dong, Mengjie Cao, Jinjuan Zheng, Qingling Wei, Chunlei Yuan   +6 more
doaj   +1 more source

Table_1_Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.docx [PDF]

, 2023
IntroductionTryptophan metabolism is indirectly involved in immune tolerance and promotes response to anticancer drugs. However, the mechanisms underlying tryptophan metabolism and immune landscape in bladder urothelial carcinoma (BLCA) are not fully ...
Linlin Xue (8462736), Zhaocun Zhang (739108), Guanwen Zhou (12080054), Haifeng Zhao (607312), Guoliang Qin (16753563)   +4 more
core   +1 more source

Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes

Journal of Immunology Research, 2022
Background. Bladder cancer (BLCA) is one of the most common cancers and ranks ninth among all cancers. Extracellular matrix (ECM) genes activate a number of pathways that facilitate tumor development.
Hongfan Zhao, Zihao Chen, Yunze Fang, Mingqiang Su, Yipeng Xu, Zhifeng Wang, Michael Adu Gyamfi, Junfeng Zhao   +7 more
doaj   +1 more source

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source

Cancer heterogeneity explored through immune cell deconvolution of the tumor microenvironment

Quantitative Biology, Volume 14, Issue 3, September 2026.
Abstract Cancer is a highly heterogeneous disease, characterized by significant variability across multiple dimensions. This diversity has been extensively studied from various perspectives. In this study, we aim to examine cancer heterogeneity through the lens of immune cell composition within the tumor microenvironment.
Limin Jiang, Chung‐I Li, Rui Xin, Jijun Tang, Yan Guo   +4 more
wiley   +1 more source

A metabolic reprogramming-related gene signature correlates with prognosis and proliferation of BLCA

Discover Oncology
Bladder cancer (BLCA) is one of the most frequent urothelium carcinoma, but with poor prognosis due to lack of reliable predictive biomarkers. Metabolic reprogramming involving in various nutrients, and is reported to be closely associated with malignant progression in BLCA.
Yaoxin Wu, Yi Luo, Tinghao Li
openaire   +3 more sources

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang, D. Q. Cai, Zhen Zhao, Zhixiang Jian, Mude Shi, Yajin Chen, Jueming Chen, Chunhua Qu, Diankui Cai   +8 more
wiley   +1 more source